Entering text into the input field will update the search result below

Sickle cell players in the green after 60 Minutes piece

  • Biotechs developing gene therapies for sickle cell disease are seeing a modest uptick in buying after a 60 Minutes segment last night on the preliminary success of an unnamed gene therapy. The patient who was the primary focus appeared to have completely responded and she has been pain-free from vaso-occlusive crises since receiving the one-time treatment.
  • Selected tickers: bluebird bio (BLUE +4.8%), CRISPR Therapeutics (CRSP +3%), Vertex Pharmaceuticals (VRTX +1.4%), Editas Medicine (EDIT +3.8%)

Recommended For You

Related Stocks

SymbolLast Price% Chg
BLUE--
bluebird bio, Inc.
CRSP--
CRISPR Therapeutics AG
VRTX--
Vertex Pharmaceuticals Incorporated
EDIT--
Editas Medicine, Inc.